Skip to content

Effection of tetasip on glucocorticoid reduction in children with active lupus erythematosus: an observational study

Effection of tetasip on glucocorticoid reduction in children with active lupus erythematosus: an observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061500
Enrollment
Unknown
Registered
2022-06-27
Start date
2022-06-20
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood-onset Systemic Lupus Erythematosus (SLE)

Interventions

case series:None

Sponsors

Children's Hospital Affiliated to Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Aged 5 to 17 years at the time of enrollment; 2. Patients diagnosed with active SLE met at least 4 of the 11 criteria for SLE as revised by the American College of Rheumatology in 1997.

Exclusion criteria

Exclusion criteria: Subjects who are participating in clinical research of other drugs;

Design outcomes

Primary

MeasureTime frame
Glucocorticoid dosage;Child quality of life score;Adverse events and serious adverse events;

Secondary

MeasureTime frame
Growth and development index;Lupus activity index;SELENA-SLEDAI score;General physician assessment;Parent general assessment;

Countries

China

Contacts

Public ContactTang Xuemei
tangxuemei2008@163.com+86 13012352441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026